Allogene Therapeutics, Inc. Deferred Federal, State and Local, Tax Expense (Benefit)
Allogene Therapeutics, Inc. (ALLO) reported Deferred Federal, State and Local, Tax Expense (Benefit) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2022-02-23
- Allogene Therapeutics, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2021 was $0.00.
- Allogene Therapeutics, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2020 was $0.00.
- Allogene Therapeutics, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2019 was -$332.00K.
- Allogene Therapeutics, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2018 was -$119.00K.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 1 month | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-23 | |
| 2020-12-31 | $0.00 10-K · filed 2022-02-23 | |
| 2019-12-31 | -$332.00K 10-K · filed 2022-02-23 | |
| 2018-12-31 | -$119.00K 10-K · filed 2021-02-25 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |